Post by
Idvhmz123 on Apr 28, 2021 10:51am
DELC.TO News Release - GREAT NEWS
2021-04-28 08:30 ET - News Release Delic's Acquisition Target, Complex Biotech Discovery Ventures Ltd., Announces Hire of New Lead Chemist, Dr. Eric Janusson Canada NewsWire VANCOUVER, BC, April 28, 2021 VANCOUVER, BC, April 28, 2021 /CNW/ - Delic Holdings Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce that its acquisition target, Complex Biotech Discovery Ventures Ltd. ("CBDV"), a licensed cannabis and psilocybin research laboratory specializing in chemical analytics, extraction optimization, and process design, has hired Dr. Eric Janusson as Lead Chemist. Dr. Eric Janusson is an analytical organometallic chemist specializing in real-time methods for the quantification and characterization of sensitive chemical intermediates. A long-time resident of Vancouver Island, Dr. Janusson received his Ph.D. in analytical chemistry at the University of Victoria in 2017 under the direction of Professor Scott McIndoe. After completing his studies, Dr. Janusson held a postdoctoral scholar position with the Cronin Group at the University of Glasgow where he developed an interest in machine learning, statistical modelling, self-assembly of inorganic nanoparticles, automated synthesis and robotics, as well as ion mobility mass spectrometry. Dr. Janusson was a postdoctoral researcher at the University of Glasgow, Scotland from 2017 to 2019 in the Cronin Group. After completing his contract with the Cronin Group, he continued on as an associate member until March 2021. Dr. Janusson joined CBDV in 2021 to spearhead the analytical chemistry efforts of the company and further develop high-quality analytical methods for cannabis and psilocybin research. As Lead Chemist, Dr. Janusson's function and main duties within the company include: Lead analytical chemistry efforts Lead method development for cannabis and mushroom testing Provide input on scientific leadership and strategic direction for the company Build alliances and partnerships with other scientific experts/organizations Dr. Markus Roggen, Director of Delic Corp & Founder of CBDV commented, "We are excited to have Eric join us. He brings a lot of expertise in analytical chemistry and new perspectives to the team. Eric is instrumental to combine our analytical platforms with our machine learning capabilities." Financing DELIC and CBDV, would also like to announce a private placement of a minimum of 3,333,333 subscription receipts of CBDV ("the Subscription Receipts") on a non- brokered basis ("the Offering"), at a size to be determined in the context of the market. Each Subscription Receipt will, following the completion of the Company's transaction to acquire CBDV, entitle the holder to receive, without payment of additional consideration or taking of further action, one unit of the Company (each, a "Unit" and collectively, the "Units"), at a price CAD$0.30, with each Unit being comprised of one common share (a "CBDVCommon Share") of the Company and one common share purchase warrant of the Company ("CBDVWarrant"). Each CBDV Warrant shall be exercisable to acquire one CBDV Common Share of the Company at a price of CAD$0.40 per CBDV Warrant for a period of twenty-four (24) months.